SARA RICHESON: Open Payments
NPI 1720566797 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,273 in 57 payments from 16 companies in 2025. Trend: 2023 $1,410 · 2024 $1,643 · 2025 $1,273
Food & beverage: $1,273
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $291 |
| Madrigal Pharmaceuticals | 5 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $183 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $93 |
| Janssen Biotech, Inc. | 3 | $65 |
| Lilly USA, LLC | 3 | $62 |
| GENZYME CORPORATION | 2 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Braintree Laboratories, Inc. | 2 | $43 |
| Gilead Sciences, Inc. | 2 | $42 |
Products named: REZDIFFRA, RINVOQ, ENTYVIO, DUPIXENT, XIFAXAN, TREMFYA, OMVOH, SKYRIZI.
Industry payments across IN — which companies pay providers there.
